Oncotelic Therapeutics, Inc. (OTLC) Form 10-Q — Aug 13, 2026
Oncotelic Therapeutics' 10-Q for the quarter ended June 30, 2026 raises substantial doubt about the company's ability to continue as a going concern. Cash and restricted cash stood at just $206,014 against negative working capital of roughly $16.4 million, and management explicitly states it does not believe it has sufficient cash for the next twelve months. The company posted a six-month net loss of about $1.9 million versus a $154,000 loss a year earlier, with operating expenses jumping to $2.9 million from $167,000.
Key figures
- Eps
- -0.00
- Revenue
- 250000
- Total Assets
- 394750732
- Cash Position
- 206014
- Q2 2026 net income
- 341011
- Jv ownership percent
- 45
- Negative working capital
- $16.4 million
- Lunai investment fair value
- 1400000
- Lunai preferred stated value
- $12.5 million
- Ppm2 to ppm3 debt conversion
- $2.2 million
- Six month operating expenses
- 2946950
- Deferred income tax liability
- 111550000
- Prior year six month net loss
- 153815
- Shares outstanding aug 13 2026
- 457512796
- Shares outstanding jun 30 2026
- 457012796
- Stock price used in valuations
- $0.04
- Contingent consideration point R
- 2625000
- Gmp notes in default outstanding
- $5.0 million
- Mast hill equity line commitment
- $25 million
- Mast hill jan 2026 note principal
- 398333
- May 2022 note converted into shares
- 11877507
- Mast hill equity line drawn jun 2026
- $6,600
- Pacific pier jun 2026 note principal
- 178410
- Gmp bio preliminary pipeline valuation
- $2.3 billion
- Q2 2026 net income attributable to oncotelic
- 388147
- Net cash used in operating activities 6m 2026
- 434440
AI analysis
Red flags10 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.